Products may not be approved for sale as in vitro diagnostics in all countries.
Please contact us for further details.
Customers in the US, please contact MBL International Corporation for details.

MDA5 Webinar

MDA5 Webinar

Product Code No. Size Method RUO/IVD/
Anti-Synthetase ELISA Kit 7840R 96 wells ELISA RUOアイコン
MESACUP™ anti-MDA5 TEST 7874E 96 wells ELISA CE-IVDアイコン eIFUアイコン SDSアイコン
Anti-TIF1-γ ELISA Kit 7854R 96 wells ELISA RUOアイコン
Anti-Mi-2 ELISA Kit 7844R 96 wells ELISA RUOアイコン

RUOアイコン : Research Use Only Reagent
CE-IVDアイコン : CE-marked In vitro Diagnostic Reagent

Polymyositis and dermatomyositis (PM/DM) are systemic autoimmune disorders that involve muscle, skin and lungs. A number of autoantibodies are detected in PM/DM patient sera, some of which are specific to PM/DM (known as myostis-specific autoantibodies; MSAs) (1).
In addition to well characterized MSAs, such as anti-aminoacyl tRNA synthetase (ARS), anti-signal recognition particle, and anti-Mi-2 antibodies, a number of additional DM specific antibodies have been recently described. These include antibodies against melanoma differentiation-associated gene 5 (MDA5), transcriptional intermediary factor-1-gamma (TIF1-γ) (2).


  1. Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925-33.
  2. Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, et al. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS One. 2016;11(4):e0154285.


Anti-MDA5 Antibody
Biomarker for Diagnosis and Prognosis of Dermatomyositis (DM) with Interstitial Lung Disease (ILD)

Ran Nakashima, MD, PhD
Rheumatology and Clinical Immunology, Kyoto University Hospital